Irritable bowel syndrome

Disease-a-Month

Volumn 48, Issue 2, 2002, Pages 101-143

  Birrer, Richard B ^a  

^a St Joseph's Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ALPRAZOLAM; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANXIOLYTIC AGENT; ATROPINE PLUS DIPHENOXYLATE; BELLADONNA ALKALOID; CALCIUM CHANNEL BLOCKING AGENT; CHLORDIAZEPOXIDE; CLIDINIUM; COLESTYRAMINE; DIAZEPAM; DICYCLOVERINE; DIPHENOXYLATE; FEDOTOZINE; LOPERAMIDE; LOXIGLUMIDE; MEBEVERINE; OTILONIUM BROMIDE; PINAVERIUM; PROKINETIC AGENT; SECBUTABARBITAL; SEDATIVE AGENT; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; UNINDEXED DRUG;

ADULT; ANXIETY NEUROSIS; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CASE REPORT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COLON DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DIETARY FIBER; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE INNERVATION; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; META ANALYSIS; MULTICENTER STUDY; PAIN; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; PSYCHOTHERAPY; TREATMENT PLANNING;

EID: 0036120062     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1067/mda.2002.122480     Document Type: Article

References (208)

1. Irritable bowel syndrome
2. A biopsychosocial understanding of the irritable bowel syndrome: A review
3. Functional bowel disorders and functional abdominal pain
4. Functional digestive disorders (FDD) in the year 2000: Economic impact
5. The irritable bowel syndrome: Review and a graduated multicomponent treatment approach
6. Functional bowel disorders: Are they independent diagnoses?
7. Irritable bowel syndrome
8. Esophageal chest pain: Current controversies in pathogenesis, diagnosis, and therapy
9. Psychological factors in functional gastrointestinal disorders: Characteristics of the disorder or of the illness behavior
10. Survey of the AGA membership relating to patients with functional gastrointestinal disorders
11. The epidemiology of functional gastrointestinal disorders in North America
12. Epidemiology of irritable bowel syndrome in the United States
13. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization, and quality of life
14. Irritable bowel syndrome in the general population
15. The impact of irritable bowel syndrome on health-related quality of life
16. Functional bowel disorders survey
17. Medical costs in community subjects with irritable bowel syndrome
18. Health-care utilization and economic issues in irritable bowel syndrome
19. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom
20. Clinical economics review: Irritable bowel syndrome
21. Irritable bowel syndrome in a community: Symptoms subgroups, risk factors, and health-care utilization
22. U.S. Householder Survey of Functional Gastrointestinal Disorders: Prevalence sociodemography, and health impact
23. Gender differences in irritable bowel syndrome
24. Review article: Gender-related differences in functional gastrointestinal disorders
25. Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters
26. Simplified assessment of segmental colonic transit
27. Irritable bowel syndrome
28. Irritable bowel syndrome defined by factor analysis: Gender and race comparisons
29. Feminine gender role and illness behaviour in irritable bowel syndrome
30. Abdominal pain and irritable bowel syndrome in adolescents: A community-based study
31. Symptoms of irritable bowel in school children: Prevalence and psychosocial effects
32. Characterization of symptoms in children with recurrent abdominal pain: Resemblance to irritable bowel syndrome
33. Recurrent abdominal pain: A potential precursor of irritable bowel syndrome in adolescents and young adults
34. The irritable bowel syndrome in the elderly
35. Prevalence of gastrointestinal symptoms in the elderly: A population-based study
36. Irritable bowel syndrome in the elderly
37. The epidemiology of irritable bowel syndrome in a random population: Prevalence, incidence, natural history, and risk factors
38. Gender role and irritable bowel syndrome: Literature review and hypothesis
39. The irritable bowel syndrome and functional dyspepsia: Familial disorders?
40. Intergenerational transmission of gastrointestinal illness behavior
41. Familial association in adults with functional gastrointestinal disorders
42. Evidence of genetic contribution to functional bowel disorder
43. Risk factors for irritable bowel syndrome: Role of analgesics and food sensitivities
44. Risk factors in irritable bowel syndrome
45. Exclusion diets in irritable bowel syndrome: Are they worthwhile?
46. Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people
47. Evolving concepts in irritable bowel syndrome
48. Gender differences in regional brain response to visceral pressure in IBS patients
49. Evidence for autonomic nervous system imbalance in women with irritable bowel syndrome
50. The effect of anger on colon motor and myoelectric activity in irritable bowel syndrome
51. Cholecystokinin's role in the regulation of colonic motility in health and in irritable bowel syndrome
52. Autonomic dysfunction in gastrointestinal motility disorders
53. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities
54. Regional brain activity before and after visceral sensitization
55. Abdominal pain in irritable bowel syndrome
56. Regional cerebral activity in normal and pathologic perception of visceral pain
57. Gastric dysrhythmias and delayed gastric emptying in patients with functional dyspepsia
58. Irritable bowel syndrome: A technical review for practice guideline development
59. Correlation of symptoms criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients
60. Perceptual responses in patients with inflammatory and functional bowel disease
61. Altered rectal perception is a biological marker of patients with irritable bowel syndrome
62. The role of psychological and biological factors in postinfective gut dysfunction
63. Psychometric scores and persistence of irritable bowel after infectious diarrhea
64. Prevalence of gastrointestinal symptoms 6 months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients
65. Irritable bowel syndrome - Post salmonella infection
66. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study
67. The role of psychological and biological factors in postinfective gut dysfunction
68. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome
69. Corticotropin-releasing factor and the brain-gut motor responses to stress
70. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease
71. Disturbed motilin and cholecystokinin release in the irritable bowel syndrome
72. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: In vitro studies of carbohydrate fermentation
73. Anxiety and the irritable bowel syndrome: Psychiatric, medical, or both?
74. Symptoms duration in patients with irritable bowel syndrome
75. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome
76. Noncolonic features of irritable bowel syndrome
77. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time
78. Intestinal and extraintestinal symptoms in functional gastrointestinal disorders
79. Self-reported abuse and gastrointestinal disease in outpatients: Association with irritable bowel-type symptoms
80. Is the association between irritable bowel syndrome and abuse explained by neuroticism? A population based study
81. Symptoms of psychological distress associated with irritable bowel syndrome
82. The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome
83. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquire
84. Life events, psychiatric illness, and the irritable bowel syndrome
85. Prevalence of psychiatric disorders in patients with irritable bowel syndrome
86. The relationship of irritable bowel syndrome and panic disorder
87. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome
88. Panic disorder associated with gastrointestinal disease: Review and hypotheses
89. Psychopathology of functional disorders of the gut
90. Functional bowel disorders: A multicenter comparison of health status, and development of illness severity index
91. Predictors of health-care seeking for irritable bowel syndrome: A population based study
92. Health status by gastrointestinal diagnosis and abuse history
93. Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates
94. On certain painful affections of the intestinal canal
95. Towards positive diagnosis in the irritable bowel syndrome
96. A diagnostic score for the irritable bowel syndrome: Its value in the exclusion of organic disease
97. Kruis scoring system and Manning's criteria in diagnosis of irritable bowel syndrome: Is it better to use combined?
98. Evaluation of Manning's criteria in the diagnosis of irritable bowel syndrome
99. Irritable bowel syndrome. Still far from a positive diagnosis
100. French experience of Manning's criteria in irritable bowel syndrome
101. Manning criterial in irritable bowel syndrome: Its diagnostic significance
102. Diagnostic value of the Manning criteria in irritable bowel syndrome
103. Irritable bowel syndrome: Guidelines for the diagnosis
104. Functional bowel disorders and functional abdominal pain
105. Rome II: A multinational consensus: Document on functional gastrointestinal disorders
106. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome
107. Diagnosing irritable bowel syndrome: Predictive values of the Rome criteria
108. Irritable bowel syndrome: Which definitions are consistent?
109. Irritable bowel syndrome symptom patterns, frequency, duration, and severity
110. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome
111. More accurate diagnosis of irritable bowel syndrome by use of noncolonic symptomatology
112. Irritable bowel syndrome: A technical review for practice guideline development
113. Management of the irritable bowel syndrome
114. Utility of screening tests in irritable bowel syndrome
115. Treatment strategies for functional gastrointestinal disorders
116. Is rectal biopsy necessary in irritable bowel syndrome?
117. Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome?
118. Irritable bowel syndrome: Prognosis and diagnostic safety. A 5-year follow-up study
119. Potential pitfalls in the differential diagnosis of irritable bowel syndrome
120. Evaluation and management of constipation
121. AGA technical review on the evaluation on the evaluation and management of chronic diarrhea
122. Irritable bowel syndrome
123. Primary fibromyalgia and the irritable bowel syndrome: Different expressions of a common pathogenetic process
124. Bowel dysfunction in fibromyalgia syndrome
125. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients
126. The prevalence and implications of irritable bowel syndrome in female fibromyalgia patients
127. Brit Soc Gastroenterol, Guidelines for the management of the irritable bowel syndrome
128. Irritable bowel syndrome: A cost-effective approach for primary-care physicians
129. Controlled treatment trials in the irritable bowel syndrome: A critique
130. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome
131. Calcium polycarbophil compared with placebo in irritable bowel syndrome
132. Ispaghula therapy in the irritable bowel syndrome: Improvement in overall well-being is related to reduction in bowel dissatisfaction
133. Irritable bowel syndrome
134. Bran supplementation in the treatment of irritable bowel syndrome
135. Bran and irritable bowel syndrome: Time for reappraisal
136. Clinical response to dietary fiber treatment of chronic constipation
137. Diet and the irritable bowel syndrome
138. Management of patients with food intolerance in irritable bowel syndrome: The development and use of an exclusion diet
139. Irritable bowel syndrome: Current concepts and future prospects
140. Systematic reviews: Synthesis of best evidence for clinical decisions
141. A double-blind, placebo-controlled trial with loperamide in irritable bowel syndrome
142. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study
143. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials
144. The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: An uncontrolled open multicenter study
145. Selective slowing of proximal colon transit in irritable bowel syndrome by cholecystokinin-receptor antagonist loxiglumide
146. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study
147. Long-term treatment of irritable bowel syndrome with cimetropium bromide: A double-blind placebo-controlled trial
148. Zamifenacin (UK-76,654), a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome
149. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome
150. Muscarinic antagonists in development for disorders of smooth muscle function
151. Trimebutine: Mechanism of action, effects on gastrointestinal function, and clinical results
152. Octylonium bromide in the treatment of the irritable bowel syndrome: A clinical-functional study
153. Mebeverine alters small bowel motility in irritable bowel syndrome
154. Otilonium bromide in the irritable bowel syndrome: A double-blind, placebo-controlled, 15-week study
155. Peppermint oil for the irritable bowel syndrome: A multicenter trial
156. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
157. The mechanism of action of peppermint oil on gastrointestinal smooth muscle
158. Peppermint oil for irritable bowel syndrome: A critical review and meta-analysis
159. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind, placebo-controlled trial
160. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome
161. Antidepressant therapy in 138 patients with irritable bowel syndrome: A 5-year clinical experience
162. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome
163. Influence of antidepressants on whole gut and orocecal transit times in health and irritable bowel syndrome
164. Symptom relief with amitriptyline in the irritable bowel syndrome
165. Antidepressants for functional gastrointestinal syndromes
166. Approaches to the modulation of abdominal pain
167. The effects of desipramine on IBS compared with atropine and placebo
168. Comparison of various treatments for irritable bowel syndrome
169. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome
170. New drugs in the management of the irritable bowel syndrome
171. Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions
172. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)
173. Five-hydroxytryptamine and functional bowel disorders
174. Review article: The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome
175. Effect of a 5-HT3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome
176. Reduction in rectal sensitivity and postprandial motility by granisetron, a 5-HT3 receptor antagonist, in patients with irritable bowel syndrome
177. Selective 5-HT3 antagonism: A role in irritable bowel syndrome and functional dyspepsia?
178. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin
179. New therapies for functional bowel diseases
180. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study
181. Octreotide reduces perception of rectal electrical stimulation by spinal afferent inhibition
182. Management of irritable bowel syndrome: Novel approaches to the pharmacology of gut motility
183. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients
184. Management of diarrheic type of irritable bowel syndrome with exclusion diet and disodium comoglycate
185. Beta-blockade in irritable-bowel syndrome: An assessment in anxious patients with diarrhea
186. Treatment of irritable colon with lidamidine and support psychotherapy
187. Alternative therapy methods in functional disorders of the gastrointestinal system
188. The role of acupuncture in the treatment of irritable bowel syndrome: A pilot study
189. Treatment of the irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial
190. Psychological treatment for irritable bowel syndrome: A critique of controlled treatment trials
191. Psychiatric disorder and outcome in irritable bowel syndrome
192. The combination of medical treatment plus multicomponent behavioral therapy superior to medical treatment alone in the therapy of irritable bowel syndrome
193. A multilevel data analytic approach for evaluation of relationships between daily life stressors and symptomatology: The case of irritable bowel syndrome
194. A controlled trial of psychological treatment for the irritable bowel syndrome
195. Cognitive therapy for irritable bowel syndrome
196. Cognitive-behavioral group therapy for irritable bowel syndrome: Effects and long-term follow-up
197. Relaxation training as a treatment for irritable bowel syndrome
198. The irritable bowel syndrome: Long-term prognosis and the physician-patient interaction
199. Irritable bowel syndrome: The view from general practice
200. Prognosis in the irritable bowel syndrome: A 5-year prospective study
201. Prevalence, incidence, and prognosis of gastrointestinal symptoms in a random sample of an elderly population